Company profile: iosBio
1.1 - Company Overview
Company description
- Provider of thermally stable oral vaccine platforms and services, offering vaccine manufacturing, distribution, and delivery. Its OraPro technology uses viral vectors to deliver capsule-based vaccines to the GI tract, enabling mucosal and systemic immunity without cold-chain storage. Products include OraPro and OraPro-Covid-19, an at-home oral vaccine targeting S and N proteins.
Products and services
- Vaccine Manufacturing, Distribution, and Delivery: iosBio produces end-to-end vaccine manufacturing, distribution, and delivery services, leveraging viral vector-based development to rapidly and cheaply engineer products for GI-tract administration and mucosal/systemic immunity
- OraPro: A thermally stable oral platform that delivers vaccines via mucosal surfaces to the GI tract in capsule form, enabling mucosal and systemic immunity without cold chain storage
- OraPro-Covid-19: A thermally stable oral Covid-19 vaccine engineered on OraPro for at-home administration, targeting S- and N-proteins to elicit mucosal and systemic immunity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to iosBio
Appili Therapeutics
HQ: Canada
Website
- Description: Provider of anti-infective pharmaceutical development solutions, addressing unmet medical needs with improvements to established therapies and new classes of anti-infectives. Pipeline includes ATI-1701, a live-attenuated tularemia vaccine candidate; ATI-1801, a topical antiparasitic for cutaneous leishmaniasis; and LIKMEZ (ATI-1501), an oral taste-masked metronidazole suspension.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Appili Therapeutics company profile →
Pardes Bio
HQ: United States
Website
- Description: Provider of direct-acting antivirals for the treatment of coronavirus, applying modern reversible-covalent chemistry to discover and develop novel oral drug candidates starting with COVID-19, as a clinical-stage biopharmaceutical company focused on improving patient access to these medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pardes Bio company profile →
Altesa BioSciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on accelerating the development of new treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altesa BioSciences company profile →
Fluoresentric
HQ: United States
Website
- Description: Provider of assay design, optimization, and custom manufacturing services for the healthcare and biotechnology sector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluoresentric company profile →
Lodo Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery and development focused on creating naturally derived novel therapeutics to impact global human health, working in partnership with global pharmaceutical companies and leading NGOs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lodo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for iosBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to iosBio
2.2 - Growth funds investing in similar companies to iosBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for iosBio
4.2 - Public trading comparable groups for iosBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →